Overview
RNAC market data
Price History
RNAC price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$5.02 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.63 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.60 – $14.56 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $214.3 · P/B 2.17 · P/S 120.75.
Company News
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease MarketBenzinga · Jun 9, 2026, 5:35 PM
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price TargetBenzinga · Jun 9, 2026, 5:00 PM
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price TargetBenzinga · Jun 9, 2026, 4:40 PM
8-K filing — Cartesian Therapeutics, Inc. (RNAC)SEC EDGAR · Jun 9, 2026, 11:16 AM
Cartesian Therapeutics Inks Licensing Agreement With Westgene Biopharma For In Vivo Chimeric Antigen Receptor T-cell Therapies In Autoimmune Diseases, For Undisclosed Upfront And Milestone PaymentsBenzinga · Jun 9, 2026, 11:15 AM
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsightGlobenewswire Inc · Jun 2, 2026, 5:15 PM
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price TargetBenzinga · May 27, 2026, 1:40 PM
Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $40Benzinga · May 26, 2026, 4:32 PM
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027Globenewswire Inc · May 26, 2026, 11:15 AM
Cartesian Therapeutics Announces Non-Dilutive Financing Of Up To $150M From K2 HealthVentures; Expects Topline Data From Phase 3 AURORA Trial In Q1 2027Benzinga · May 26, 2026, 11:05 AM